EuroBiotech: More Articles of Note


> Autolus completed the first-dose cohort in a phase 1/2 trial of its CAR-T candidate. The multiple myeloma trial will provide an early test of its dual-targeting approach to CAR-T, which makes two changes to patients’ T cells in an attempt to stop tumors evading detection. Statement | FT

> Cell Medica named Luis Borges, Ph.D., as its CSO. Borges joins the T cell biotech from Five Prime Therapeutics, where he rose through the ranks to the position of SVP of research before making way for Bryan Irving, Ph.D. Release

> European regulators rejected AB Science’s masitinib for the second time in 16 months. The latest rejection followed a reassessment of the evidence to support use of the drug in adult patients with smoldering or indolent systemic severe mastocytosis. AB shares slipped more than 20% in the days following the news. Statement


Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

> Pharnext changed the protocol of its phase 3 Charcot-Marie-Tooth disease type 1A trial. The trial will now give patients in the high-dose arm of the trial’s nine-month extension double the amount of the low dose, not the high-dose formulation. Pharnext made the change after learning of stability problems with the high-dose formulation. Release

> Enterome unveiled plans to move its research laboratories to the Genopole biocluster. The move will affect 15 of the microbiome specialist's 40 employees. Statement

> Life sciences crowdfunding platform Capital Cell opened up to investors in the U.K. Release 

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.